Author Interviews, Heart Disease / 15.04.2016
Idarucizumab– PRAXBIND Reverses Anticoagulant Effects of Dabigatran
MedicalResearch.com Interview with:
Dr. Charles Pollack MD MA
Thomas Jefferson University
Philadelphia, PA 19107
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Pollack:: We are continuing research on PRAXBIND in the ongoing global phase III patient study, RE-VERSE AD™. RE-VERSE AD includes two groups of dabigatran patients: those who had serious bleeding or those who required an urgent procedure.
At ACC, we presented results from an updated interim analysis from 123 patients enrolled in RE-VERSE AD™, which showed a single 5g of PRAXBIND immediately reversed the anticoagulant effect of dabigatran in all patients evaluated.
(more…)